Skip to main content
. 2012 May 30;22(6):848–860. doi: 10.1111/j.1750-3639.2012.00600.x

Figure 2.

Figure 2

Nestin positivity is a marker of poor prognosis in primary ependymoma and discriminates WHO II ependymoma with poor survival. The n = 379 primary ependymoma samples on a tissue microarray (TMA) were stained for nestin and scored for negativity or positivity. Progression‐free survival (PFS; top row) and overall survival (OS; bottom row) of all (left), pediatric only (middle) and adult only (right) patients. A. Nestin seprates the cohorts (all, pediatric only or adult only) into two distinct groups with statistically significant different PFS or OS probabilities (logrank‐test). B. WHO II nestin‐postive tumors have the same poor prognosis as WHO III nestin‐negative tumors: in all analyses (PFS or OS for all, pediatric or adult), no significant differences could be detected between WHO II nestin‐positive tumors and WHO III nestin‐negative tumors (logrank‐test). WHO II tumors positive for nestin have a significantly inferior PFS in all, pediatric and adult patients, and a significantly inferior OS in all and adult patients (logrank‐test).